TY - JOUR
T1 - A clinicopathologic study of diencephalic pediatric low-grade gliomas with BRAF V600 mutation
AU - Ho, Cheng Ying
AU - Mobley, Bret C.
AU - Gordish-Dressman, Heather
AU - VandenBussche, Christopher J.
AU - Mason, Gary E.
AU - Bornhorst, Miriam
AU - Esbenshade, Adam J.
AU - Tehrani, Mahtab
AU - Orr, Brent A.
AU - LaFrance, Delecia R.
AU - Devaney, Joseph M.
AU - Meltzer, Beatrix W.
AU - Hofherr, Sean E.
AU - Burger, Peter C.
AU - Packer, Roger J.
AU - Rodriguez, Fausto J.
PY - 2015/10/26
Y1 - 2015/10/26
N2 - Among brain tumors, the BRAFV600E mutation is frequently associated with pleomorphic xanthoastrocytomas (PXAs) and gangliogliomas (GGs). This oncogenic mutation is also detected in ~5 % of other pediatric low-grade gliomas (LGGs) including pilocytic astrocytomas (PAs) and diffuse astrocytomas. In the current multi-institutional study of 56 non-PXA/non-GG diencephalic pediatric LGGs, the BRAFV600 mutation rate is 36 %. V600-mutant tumors demonstrate a predilection for infants and young children (V600-mutant tumors appear as nodular, yet infiltrative contrast-enhancing masses. Morphologic examination reveals a monophasic, predominantly compact and partially infiltrative architecture. Due to the lack of classic morphologic features associated with PAs, pilomyxoid astrocytomas (PMAs), or diffuse astrocytomas, 75 % of the BRAFV600-mutant tumors could not be definitively classified on initial histopathologic evaluation. At a median follow-up of 55 months, the 5-year progression-free survival (PFS) rate for BRAFV600-mutant diencephalic low-grade astrocytomas (LGAs) was 22 ± 12 %, shorter than BRAFV600-WT PAs (52 ± 13 %) but higher than PMAs (10 ± 6 %). Of note, long-term PFS was observed in several adolescent patients with BRAFV600-mutant tumors. In children aged 0–12 years, 5-year PFS rate and median PFS in BRAFV600-mutant LGAs are 9 ± 9 % and 19 months (95 % CI 3–37 months), respectively. The PFS is comparable to that in BRAFV600-WT PMAs (5-year PFS rate: 10 ± 9 %; median PFS: 15 months, 95 % CI 3–32 months; p = 0.96) and significantly shorter than BRAFV600-WT PAs (5-year PFS rate: 46 ± 13 %; median PFS: 51 months, 95 % CI 20–∞ months; p < 0.05). In summary, diencephalic BRAFV600-mutant pediatric LGAs are associated with unique clinicopathologic features and have a more aggressive clinical course, especially in children under age 13. The low rate of CDKN2A deletion also suggests that these tumors are molecularly distinct from secondary pediatric high-grade gliomas.
AB - Among brain tumors, the BRAFV600E mutation is frequently associated with pleomorphic xanthoastrocytomas (PXAs) and gangliogliomas (GGs). This oncogenic mutation is also detected in ~5 % of other pediatric low-grade gliomas (LGGs) including pilocytic astrocytomas (PAs) and diffuse astrocytomas. In the current multi-institutional study of 56 non-PXA/non-GG diencephalic pediatric LGGs, the BRAFV600 mutation rate is 36 %. V600-mutant tumors demonstrate a predilection for infants and young children (V600-mutant tumors appear as nodular, yet infiltrative contrast-enhancing masses. Morphologic examination reveals a monophasic, predominantly compact and partially infiltrative architecture. Due to the lack of classic morphologic features associated with PAs, pilomyxoid astrocytomas (PMAs), or diffuse astrocytomas, 75 % of the BRAFV600-mutant tumors could not be definitively classified on initial histopathologic evaluation. At a median follow-up of 55 months, the 5-year progression-free survival (PFS) rate for BRAFV600-mutant diencephalic low-grade astrocytomas (LGAs) was 22 ± 12 %, shorter than BRAFV600-WT PAs (52 ± 13 %) but higher than PMAs (10 ± 6 %). Of note, long-term PFS was observed in several adolescent patients with BRAFV600-mutant tumors. In children aged 0–12 years, 5-year PFS rate and median PFS in BRAFV600-mutant LGAs are 9 ± 9 % and 19 months (95 % CI 3–37 months), respectively. The PFS is comparable to that in BRAFV600-WT PMAs (5-year PFS rate: 10 ± 9 %; median PFS: 15 months, 95 % CI 3–32 months; p = 0.96) and significantly shorter than BRAFV600-WT PAs (5-year PFS rate: 46 ± 13 %; median PFS: 51 months, 95 % CI 20–∞ months; p < 0.05). In summary, diencephalic BRAFV600-mutant pediatric LGAs are associated with unique clinicopathologic features and have a more aggressive clinical course, especially in children under age 13. The low rate of CDKN2A deletion also suggests that these tumors are molecularly distinct from secondary pediatric high-grade gliomas.
KW - BRAF
KW - Diencephalic
KW - Hypothalamic
KW - Low-grade glioma
KW - Pilocytic astrocytoma
KW - Pilomyxoid astrocytoma
KW - V600E
UR - http://www.scopus.com/inward/record.url?scp=84942363595&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84942363595&partnerID=8YFLogxK
U2 - 10.1007/s00401-015-1467-3
DO - 10.1007/s00401-015-1467-3
M3 - Article
C2 - 26264609
AN - SCOPUS:84942363595
VL - 130
SP - 575
EP - 585
JO - Acta Neuropathologica
JF - Acta Neuropathologica
SN - 0001-6322
IS - 4
ER -